AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01801553 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal manipulation
Description: -In the intervention group :~True Lumbopelvic manipulation in supine (A) or in lateral side lying (B) for subjects with LBP:~If for example, A is the best position for both patient-practitioner but after a maximum of two trials doesn't produce a pop sound then the practitioner will move to the B position for a maximum of two trials as well.~-In the control group:~Sham spinal manipulation will realize to mimic (i) the same time, (ii) interaction and (iii) action with the manual therapist but without any efficacy in the position B using the upper body of the patient to target the thoraco-lumbar hinge and not the lumbopelvic region and take the time of handling the patient like in a true SM and mimic a high velocity and short ROM action moving fast his body but with a minimal action on the patient's body.
Study NCT01801553 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham spinal manipulation
Study NCT04917263 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry, Flow citometry, Trascriptome analysis
Description: we will perform immunohistochemistry, flow cytometry, transcriptomic analysis, mRNA microarray and mutational profiling
Study NCT02230722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Study NCT02230722 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Study NCT02916706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin 20mg
Study NCT02916706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01798862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial injury by hysteroscopy or pipelle sampling
Study NCT01798862 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proceed to COH directly
Study NCT00927524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glulisine
Description: Dose injection of insulin glargine (Lantus®) given subcutaneously in the abdomen 1 hour prior to breakfast and a dose of insulin glulisine (Apidra®) at a dose based upon your (body wt.) carbohydrate intake for each of the three meals (breakfast, lunch and dinner).
Study NCT00927524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Dose based on carbohydrate intake given subcutaneously in the abdomen prior to breakfast and dinner.
Study NCT00461643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
Study NCT00664105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be given weekly for seven weeks beginning on Day 1 of the study as a 30-minute intravenous infusion during concurrent therapy.~Carboplatin will be given once every three weeks as a 30-minute intravenous infusion immediately following the infusion of docetaxel. Patients will receive two cycles of consolidation treatment.
Study NCT00664105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be given weekly for seven weeks beginning on Day 1 of the study as a 30-minute intravenous infusion during concurrent therapy.~Docetaxel will be given once every three weeks administered as a one-hour IV infusion. Patients will receive two cycles of consolidation treatment (1 cycle = 3 weeks).
Study NCT00664105 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiotherapy will be administered daily X 5 day/week for 34 days beginning on Day 1 of the study. Radiotherapy will follow immediately after the infusions of docetaxel and carboplatin.
Study NCT02267265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TMW-Newborn Intervention video
Description: This is an educational video intervention developed by the Thirty Million Words® Initiative Lab.
Study NCT02267265 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Safe Sleep for your Baby (SIDS) educational video
Description: It is an educational video developed by the National Institute of Child Health and Development (NICHD) promoting the prevention of Sudden Infant Death Syndrome.
Study NCT02594046 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: stem cell component extract
Description: The Allogeneic Human adipose derived stem cell component extract
Study NCT02594046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stem cell component extract
Description: The Allogeneic Human adipose derived stem cell component extract
Study NCT00520767 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: ≤28 days prior to enrollment
Study NCT00520767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Day 1 of cycles 6, 12, 18 and at end of study.
Study NCT00520767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: ≤28 days prior to enrollment
Study NCT00520767 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Start of each cycle
Study NCT02942043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Group A (low dose group) Intrapleural injection of bevacizumab 2.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group B (medium dose group) Intrapleural injection of bevacizumab 5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group C (high dose group) Intrapleural injection of bevacizumab 7.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
Study NCT03998137 — intervention group
Intervention type: DEVICE
Intervention: AUGMENT® Injectable Bone Graft
Description: AUGMENT® Injectable Bone Graft
Study NCT03998137 — intervention group
Intervention type: PROCEDURE
Intervention: Standard of Care
Description: Autologous Bone Graft
Study NCT05380128 — intervention group
Intervention type: GENETIC
Intervention: Genotype analysis for VDR rs1544410, rs2228570, rs731236, and rs7975232 polymorphisms
Description: Genomic DNA was extracted from peripheral blood samples using a Wizard Genomic DNA Purification Kit (Promega, Madison,Wisconsin, USA) as per the product instruction. VDR (rs731236, rs1544410, rs7975232, rs2228570) polymorphisms were genotyped by the improved Multiple Ligase Detection Reaction (iMLDR) developed by Genesky Biotechnologies Inc. (Shanghai, China).
Study NCT02491710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training on low-cost box trainer
Study NCT02491710 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Training on standard box trainer
Study NCT03458728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (BAY806946)
Description: Copanlisib will be dosed on Day 1, Day 8, and Day 15 of every 28-day cycle. Phase 1: 2 or 3 dose cohorts may be evaluated in phase 1 of the study. Phase 2: RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
Study NCT03756168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1060nm Diode laser
Description: All subjects received a single treatment with Venus Bliss' 1064 nm laser administered to the flanks~Venus Bliss is a non-invasive medical aesthetic device designed for body contouring. The device contains four 1060 nm diode laser applicators which are 60x60 mm in size. It has a separate RF/PEMF applicator, but this was not used in this study. There is a belt included with the system to allow for the secure attachment of the applicators to the treatment area.
Study NCT04333732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR or M-M-R II ® vaccine
Description: Education and surveillance plus MR or M-M-R II ® vaccine
Study NCT04333732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection
Study NCT04587986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899
Description: Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
Study NCT04587986 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BTL-899
Description: Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
Study NCT01755910 — intervention group
Intervention type: OTHER
Intervention: Left thoracic paravertebral block
Study NCT01755910 — intervention group
Intervention type: OTHER
Intervention: Right thoracic paravertebral block
Study NCT00381797 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00381797 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo fludeoxyglucose F18 PET
Study NCT00381797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT01937195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuCath Intravenous Catheter System
Description: AccuCath IV Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal. Results will be compared to published literature for conventional IV catheters.
Study NCT04257422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intentional Rounding
Description: A new method of nursing care named Intentional Rounding. The intentional roundings are planned rounds, conducted at regular intervals by nursing staff to anticipate care, comfort, hospitality and psychological needs of hospitalized users.
Study NCT03952507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184 600 (Oral Tablet Formulation)
Description: Participants will receive 600 mg of JNJ-64417184 as oral tablet.
Study NCT03952507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184 (Oral Suspension Formulation)
Description: Participants will also receive JNJ-64417184 600 mg as oral suspension.
Study NCT05258955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural honey
Description: Natural Sidr honey based mouthwash used as intervention group B (Arm Group B) for the reduction of plaque index
Study NCT05258955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: Chlorhexidine gluconate 0.12% mouthwash is used as intervention in Group A (Arm Group A) for the comparison of plaque reduction among group A and B
Study NCT03984877 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of amyloidosis
Description: Scintigraphy and protein electrophoresis
Study NCT00478647 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GA-GCB (velaglucerase alfa)
Description: 15-60 U/kg, every other week via intravenous infusion
Study NCT03740204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-β estradiol transdermal patches with cyclic progesterone
Description: 17-β estradiol transdermal patches (100 mcg 17-β estradiol/day) with cyclic progesterone (200 mg micronized progesterone daily for 12 days every month)
Study NCT03740204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch and pill
Description: Placebo patch and pill
Study NCT00197106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg
Description: comparator
Study NCT00197106 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fluticasone propionate 2 x 100 mcg
Description: comparator
Study NCT01452737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Bowel Prep
Description: Subjects will be asked to take 4L of Golytely the day prior to procedure.
Study NCT01452737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2L Golytely/bisacodyl
Description: Subjects will be asked to take 2L Golytely and 15mg bisacodyl the day prior to procedure.
Study NCT03691545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interactive sessions
Description: This arm will receive personalized health coaching (behaviour change counseling)
Study NCT03062449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Serine
Description: Gummy containing L serine dose
Study NCT03062449 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gummy
Description: Gummy with no dosing of L Serine
Study NCT01830062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIRS
Description: Near infrared spectroscopy of at least 2 major epicardial vessels
Study NCT01830062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CACS
Description: Coronary artery calcium score assessed by multi-slice computed tomography
Study NCT00636662 — intervention group
Intervention type: OTHER
Intervention: Non-invasive diagnostic testing
Description: No patient treatment is altered by enrollment in this trial
Study NCT01565317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Achievement and Intensive Treatment (Why WAIT)
Description: Weight Achievement and Intensive Treatment (Why WAIT) is a 12 -week multidisciplinary program for weight control and intensive diabetes management designed by the Joslin Diabetes Center for application in a multidisciplinary diabetes practice environment. Participants will be enrolled in a 12-week multidisciplinary intensive weight management including diet, exercise, behavioral and educational support. Participants will be enrolled in cohorts of 10-15 participants to encourage group interaction and support. Subjects will choose to come to the Joslin clinic every Tuesday or Wednesday evening for 2 hours. Participants will exercise for an hour and will attend a didactic session in the areas of nutrition, exercise and behavioral modifications.
Study NCT03051425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt
Description: 120 mL of Yogurt containing Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus, Lactobacillus casei, Bifidobacterium animalis ssp. lactis, and Lactobacillus plantarum
Study NCT03051425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 120 mL of low-fat milk
Study NCT02466243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JBT-101
Description: Part A: 20 mg once daily on Days 1-28, then 20 mg twice daily on Days 29-84.~Part B: JBT-101 20 mg twice daily on Days 1 - 365 of the OLE.
Study NCT02466243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part A: Once daily on Days 1-28, then twice daily on Days 29-84.~Part B: Placebo twice daily on Days 1 - 365 of the OLE.
Study NCT01921907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD17137 topical treatment
Study NCT01921907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04329546 — intervention group
Intervention type: OTHER
Intervention: NA (no intervention)
Description: NA (no intervention)
Study NCT03498586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Half-normal saline
Description: Use of half-normal saline as an irrigant for open-irrigated ablation catheters
Study NCT03498586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Use of normal saline as an irrigant for open-irrigated ablation catheters
Study NCT00639769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Starting dose 30 mg/m2 Dose level -1 20 mg/m2
Study NCT00639769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: 50 mg/m2 IV over 60 minutes, plus Cisplatin 30mig/m2 IV, repeated weekly for two weeks. followed by a one-week rest. This 3-week schedule given two times to equal one 6-week cycle. Maximum of 6 cycles.
Study NCT04008147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 100mg iron fumarate
Description: 100mg iron fumarate b.i.d. for 4 consecutive days
Study NCT04008147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Burgerstein Schwangerschaft & Stillzeit
Description: contains 30 mg iron fumarate, given on 14 consecutive days
Study NCT05815823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: robotic exercise therapy
Description: Functional exercise programs such as collecting rain in a glass, grating vegetables, goalkeeper, cleaning the stove, watering flowers, wiping windows, catching fish, and exploring landscapes were applied by robotic games to the patients
Study NCT05815823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: streching, range of motion, strengthening, balance and walking exercise
Study NCT02985047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Admission
Description: Participants randomised to Brief admission (BA) will participate in a negotiation together with their out-patient clinician and a representative from the ward. The aim of the negotiation is to form an individualised contract defining how BA will work for them. After signing the contract, will have the possibility to admit themselves to hospital according to the procedure stated in the contract.
Study NCT01674920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choices
Description: The 12-week intervention included 1.5 hour classes each week. Topics included nutrition, physical activity, and psychosocial skills based in Resiliency.
Study NCT01979263 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Bias Modification Computer Task
Description: Computer task aimed at actively modifying attention bias
Study NCT01979263 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Computer Task
Description: Computer task that does not actively modify attention bias
Study NCT01939951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Activation Energy Serum
Description: 7 drops or 21 drops twice daily
Study NCT01939951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Activation Energy Serum
Description: 7 drops or 21 drops twice daily
Study NCT01592812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical muscle stimulation
Description: Duration of the stimulation 20 minutes
Study NCT04486313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Two nitazoxanide 300 mg tablets administered orally twice daily with food for 5 days
Study NCT04486313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo tablets administered orally twice daily with food for 5 days
Study NCT04486313 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin Super B-Complex
Description: Vitamin Super B-Complex administered orally twice daily to maintain the blind
Study NCT04486313 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin Super B-Complex
Description: Vitamin Super B-Complex administered orally twice daily to maintain the blind
Study NCT02609152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous perfusion of esmolol
Description: In the experimental arm of the study, a continuous perfusion of esmolol will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. At H4, the doctor in charge is free to gradually continue or stop the infusion.
Study NCT02609152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Continuous perfusion of saline
Description: In the control arm of the study, a continuous infusion of normal saline will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. A H4, the doctor in charge is free to gradually continue or stop the infusion.
Study NCT01159483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in the treatment arm
Study NCT01159483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study NCT01907113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: oral administration
Study NCT02932085 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neurostar TMS Therapy System, NeuroStar XPLOR System
Description: Repetitive transcranial magnetic stimulation
Study NCT01583205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Effectiveness Training - ALS
Description: Eight coping effectiveness training counseling sessions.
Study NCT02932085 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurostar TMS Therapy System, NeuroStar XPLOR System
Description: Repetitive transcranial magnetic stimulation
Study NCT03182998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive Knowing your Options decision aid